by: Parent Project Muscular Dystrophy
WATCH: Avidity Biosciences – EXPLORE44 Clinical Trial Investigating AOC 1044 in Individuals Amenable to Exon 44 Skipping
Avidity Biosciences recently joined PPMD for a community webinar on February 8, 2023 to discuss the EXPLORE44™ clinical trial. EXPLORE44 is an ongoing Phase 1/2 clinical trial evaluating AOC 1044 for the treatment of individuals with Duchenne mutations amenable to exon 44 skipping. AOC 1044 is an antibody oligonucleotide conjugate (AOC™) and is designed to use an antibody to deliver an exon 44-skipping oligonucleotide to muscle and heart cells. AOC 1044 is the first of multiple AOCs Avidity is developing for the Duchenne community.
If you missed the live event, the recording can be found below.
